ArticleJournal of ginseng research2026
Neo-gintonin: production of high concentrations of lysophosphatidic acids from Korean Red ginseng marc.
Article in Journal of ginseng research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gintonin is a novel non-saponin glycolipoprotein complex that is derived from ginseng. Its functional components are lysophosphatidic acids (LPAs), which act as ligands for six G protein-coupled LPA receptor subtypes. Thus, gintonin exerts it activity through the LPA receptor signaling pathway. Previous studies have shown that crude gintonin derived from Korean Red ginseng marc (KRGM) contains approximately 0.2-0.3% LPAs. The aim of this study was to develop a method for concentrating the LPA content in KRGM-derived gintonin. Methods: First, we prepared a gintonin-enriched fraction from KRGM and removed its ethanol-insoluble portion. Then, the ethanol-soluble fraction was subjected to anion-exchange chromatography followed by gel filtration. Subsequently, the gintonin fractions were collected and freeze-dried. The presence of the glycolipoprotein complex was confirmed using SDS-PAGE and gel staining. The newly acquired product was designated neo-gintonin. Results: Compared with KRGM total extract, neo-gintonin contained 15.4-fold higher concentrations of LPA C18:2, LPA C16:0, and LPA C18:1. The approximately 66 kDa neo-gintonin was H Conclusion: We developed a novel method for extracting neo-gintonin from KRGM and demonstrated that it exerted its physiological effects via LPA receptors. Thus, KRGM is a novel gintonin source and can be upcycled to prepare high LPA-yielding neo-gintonin.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.